Shanghai Shen Lian's UB-221 drug for chronic urticaria fully enrolls phase II trial

Shanghai Shen Lian Biomedical Corporation announced the full enrollment of 145 subjects in the Phase II clinical study of UB-221, an innovative drug developed by its investee company, Yangzhou Shizhiyuan Biological Technology Co., Ltd. UB-221, originally developed by United Biomedical, Inc., is a subcutaneous humanized monoclonal antibody targeting anti-IgE, intended for conditions such as chronic spontaneous urticaria, asthma, food allergies, allergic rhinitis, and atopic dermatitis. The company, through its wholly-owned subsidiary Shanghai Ben Tiancheng Biomedical Co., Ltd., invested RMB 60 million in Yangzhou Shizhiyuan, acquiring a 20.48% stake to advance clinical trials for UB-221, UB-421, and UB-621.

UB-221 is designed to neutralize free IgE and inhibit IgE synthesis by binding to CD23 receptors on B cells, demonstrating superior pharmacological characteristics compared to similar products already on the market. The Phase II clinical study is a multi-center, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy and safety of UB-221 in patients with chronic spontaneous urticaria. Following the completion of patient enrollment, Yangzhou Shizhiyuan will proceed with subsequent clinical research in accordance with national drug registration regulations.

This strategic move aligns with Shanghai Shen Lian Biomedical Corporation's broader focus on expanding into human innovative drug development, leveraging its existing technology platforms in synthetic peptides, genetic engineering, and mRNA. The company aims to cultivate new growth drivers by progressing the development and commercialization of its innovative drug pipeline.